After further investigating and validating TCGA-GBM dataset, a total of 9 proteins (DHX9, HNRNPR, RPL3, HNRNPA3, SF1, DDX5, EIF5B, BTF3, and RPL8) among them were identified as the key candidate proteins which were related to TMZ therapy. The gene discussed is RPL3; the disease is glioblastoma.